Interview
October 25, 2016
Results from an expansion cohort of a preliminary clinical trial have
shown encouraging activity for a novel antibody-drug conjugate in
patients with heavily pretreated advanced ovarian cancer.
The
antibody-drug conjugate, PF-06647020, targets the protein tyrosine
kinase 7 (PTK7) in these patients. PTK7 has several functions in
developmental biology, including Wnt signaling and planar cell polarity.
The enzyme is overexpressed in a variety of human cancers, including
ovarian, breast, colon, lung, gastric, and esophageal, as well as in
acute myeloid leukemia.
Six of 22 evaluable patients in the
current expansion cohort responded to PF-06647020, including 1 complete
response, and an additional 12 patients had stable disease. Some
responses were durable, ranging from 6 to 10 months’ duration.....
OncLive: Could you provide an overview of the data you presented at ESMO?
Sachdev: This is an initial phase I exploration of an
antibody-drug conjugate molecule in the clinic. It started with the
traditional dose escalation design which was for patients with advanced
solid tumors. And then there were preplanned expansion groups for breast
cancer, non–small cell lung cancer and ovarian cancer.
The data
we presented were from the expansion group for ovarian cancer,
specifically,
platinum-resistant ovarian cancer patients. The data from
the dose escalation part were actually presented at last year’s ESMO in
2015. And once we reached our recommended phase II dose, then the
planned expansions were undertaken. So today, we presented data for the
27 patients who were in the ovarian cancer expansion arm.....